Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04034225 · ClinicalTrials.gov registry record · Phase 1
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
A Phase 1 study, sponsored by Sensei Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04034225 is a Phase 1 study that was terminated before completion, run by Sensei Biotherapeutics. The registered enrollment target is 25 participants.
The verdict
NCT04034225, a Phase 1 study, was terminated before completion, sponsored by Sensei Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.
Interventions
- DRUG Pembrolizumab
- DRUG SNS-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-11-11 |
| Est. Completion | 2021-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04034225
The ClinicalTrials.gov registry entry for NCT04034225 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sensei Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04034225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04034225 about?
NCT04034225 is a clinical study titled "Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN". To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.
What is the current status of trial NCT04034225?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-11-11. Estimated completion is 2021-06-28.
What interventions are being tested in trial NCT04034225?
The interventions under investigation include: Pembrolizumab (DRUG), SNS-301 (DRUG).
Who is sponsoring clinical trial NCT04034225?
This trial is sponsored by Sensei Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.